Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris
Table 3
Synopsis of the IgG autoantibody profile of the pemphigus vulgaris (PV) patients prior to rituximab (preRtx) treatment and at the time of clinical relapse (CR).